Rhythm Pharmaceuticals, Inc. RYTM Net proceeds from sales of subsidiary shares
Net proceeds from sales of subsidiary shares at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceInitialPublicOffering.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s net proceeds from sales of subsidiary shares.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s net proceeds from sales of subsidiary shares?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported net proceeds from sales of subsidiary shares of $47.16M in Q4 2025.
- What does net proceeds from sales of subsidiary shares mean?
- This represents the total cash inflow generated from the sale of equity shares to the public during an initial or follow-on offering. It is a primary indicator of the company's ability to raise capital to fund ongoing operations and development.